NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Pityriasis rubra pilaris
Evaluation at RFL site only (JFC August 2016). Prior funding approval required.

Approved as intrapleural fibrinolytics (alteplase + dornase alfa) for ongoing sepsis in association with a persistent pleural collection, who have not responded to 12-24 hours of antibiotics and simple tube drainage, or there is radiological evidence (either on ultrasound and/or CT) that the effusion is unlikely to drain due to multiple loculation; rather than referring for surgical intervention. Evaluation sites to be approved at DTCs (JFC March 2019)

Notes: The majority of trials use dornase alfa (DNase) 5 mg and alteplase (t-PA) 10 mg administered intrapleurally twice daily for up to 3 days. Administration was followed by clamping of the drain to permit the study drug to remain in the pleural space for 1 hour. One study used dornase alfa (DNase) 5 mg and alteplase (t-PA) 5 mg twice daily. 

Provider notes

• NMUH:
• Non-formulary
• RFL:
• To be used as per protocol for complex pleural infections (under evaluation)
• RNOH:
• Non-formulary
• UCLH:
• WH:
• Non-formulary

Non-healing corneal ulcers/ persistent epithelial defects. 
Under evaluation at MEH only (restricted to corneal eye disease service only, April 2017)

Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only
Approval was subject to Dr Swayne working with Dr Sofat and JFC support to agree the datacollection form and the duration of the pilot study. Duration of audit TBC (November 2016).

Diltiazem cream for transrectal ultrasound guided prostate biopsy
Twelve-month evaluation at UCLH site only (March 2015)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Empagliflozin for symptomatic neutropenia secondary to glycogen storage disease type 1b (GSD1b) or glucose 6 phosphatase catalytic subunit 3 (G6PC3) deficiencies
Approved under evaluation at UCLH only. 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Fentanyl patch for acute post-operative pain in primary knee replacement surgery
30 patient evaluation at RNOH site only. Evaluation to be reviewed at JFC (April 2015)

Amyvid (florbetapir) for Alzheimer's disease
10 patient evaluation at RFL site only. Evaluation to be reviewed at JFC (JFC September 2014 and February 2015)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Recalcitrant warts
5 patient evaluation at RFL site only (JFC March 2013)

Hyaluronic acid injection (Ostenil Plus) to prevent surgery
Approved under evaluation at RNOH only (July 2014)

RNOH: Restricted for use in accordance with the evaluation protocol by consultants in the Shoulder and Elbow Unit

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

RFL Restricted: Acute pain unresponsive to opiates (inpatient use only; initiation by Pain team consultant or consultant Anaesthetist), for the following indications:

1. Neuropathic pain and persistent post‐surgical pain, including phantom limb pain
2. In a patient with a history of high opioid consumption preceding injury/surgery
3. In pain with poor opioid responsiveness
4. In hyperalgesic states, with or without allodynia

Evaluation for RFL only (approved by DTC in July-17, updated and approved by DTC November 2020 & ratified by JFC in August-17)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Paracetamol IV for closure of the patent ductus arteriosus (PDA)
Approved second line option after ibuprofen. All eligible patients in NCL to be included in the audit. Evaluation to be reviewed at UCLH or JFC in 12 months (March 2016).

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Pitolisant for narcolepsy with or without cataplexy
Under evaluation at UCLH only (June-17)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Spinal-cord injury neuropathic pain 
Approved under evaluation for 1 year; restricted to RNOH site (March 2015)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Chronic norovirus in PID
3 patient evaluation at RFL site only (JFC January 2015)

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only.
Approval was subject to Dr Swayne working with Dr Sofat and JFC support to agree the datacollection form and the duration of the pilot study. Duration of audit TBC (November 2016).

Sirolimus for low-flow vascular malformations in the head and neck.

Evaluation for RFL only (JFC April 2018) - see local policy for use / dose.

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Sativex for Tourette’s syndrome
Evaluation for UCLH only (March-17)

Mydrane for obtaining intraoperative pupil dilatation and intracamerular anaesthesia during topical anaesthesia cataract surgery
Evaluation for MEH only (approved by DTC in January-17, ratified by JFC in April-17)